Home LiteratureArticle Details
PMID: 21622860 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 187 ·No. 1 ·2011-07-01 ·Pages 92-101

Long HM, Leese AM, Chagoury OL, Connerty SR, Quarcoopome J, Quinn LL, Shannon-Lowe C, Rickinson AB

Abstract

EBV, a B lymphotropic herpesvirus, encodes two immediate early (IE)-, >30 early (E)-, and >30 late (L)-phase proteins during its replication (lytic) cycle. Despite this, lytic Ag-induced CD8 responses are strongly skewed toward IE and a few E proteins only, all expressed before HLA I presentation is blocked in lytically infected cells. For comparison, we examined CD4(+) T cell responses to eight IE, E, or L proteins, screening 14 virus-immune donors to overlapping peptide pools in IFN-γ ELISPOT assays, and established CD4(+) T cell clones against 12 defined epitopes for target-recognition assays. We found that the lytic Ag-specific CD4(+) T cell response differs radically from its CD8 counterpart in that it is widely distributed across IE, E, and L Ag targets, often with multiple reactivities detectable per donor and with IE, E, or L epitope responses being numerically dominant, and that all CD4(+) T cell clones, whether IE, E, or L epitope-specific, show strong recognition of EBV-transformed B cell lines, despite the lines containing only a small fraction of lytically infected cells. Efficient recognition occurs because lytic Ags are released into the culture and are acquired and processed by neighboring latently infected cells. These findings suggested that lytic Ag-specific CD4 responses are driven by a different route of Ag display than drives CD8 responses and that such CD4 effectors could be therapeutically useful against EBV-driven lymphoproliferative disease lesions, which contain similarly small fractions of EBV-transformed cells entering the lytic cycle.

MeSH Terms
Antigens, Viral/biosynthesis,immunology CD4-Positive T-Lymphocytes/cytology,immunology,virology CD8-Positive T-Lymphocytes/cytology,immunology,virology Cells, Cultured Clone Cells Cytotoxicity Tests, Immunologic/methods Epitope Mapping/methods Epitopes, T-Lymphocyte/immunology Gene Expression Regulation, Viral/immunology Herpesvirus 4, Human/growth & development,immunology Humans Immediate-Early Proteins/biosynthesis,genetics,immunology Interferon-gamma/metabolism Phosphoproteins/immunology Trans-Activators/biosynthesis,genetics,immunology Virus Replication/immunology
Chemicals
Antigens, Viral BRLF1 protein, Human herpesvirus 4 BZLF1 protein, Herpesvirus 4, Human Epitopes, T-Lymphocyte Epstein-Barr virus early antigen Epstein-Barr virus early antigen diffuse component Immediate-Early Proteins Phosphoproteins SM protein, Human herpesvirus 4 Trans-Activators Interferon-gamma
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Long Heather M
School of Cancer Sciences and Medical Research Council Centre for Immune Regulation, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom.
Leese Alison M
Chagoury Odette L
Connerty Shawn R
Quarcoopome Jared
Quinn Laura L
Shannon-Lowe Claire
Rickinson Alan B
References (49)
49 references, click to expand
  1. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
    Transplantation. 1994 Aug 15;58(3):317-24 PMID: 8053055
  2. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
    J Virol. 2001 Sep;75(18):8649-59 PMID: 11507210
  3. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection.
    J Exp Med. 2003 Sep 15;198(6):903-11 PMID: 12975456
  4. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.
    J Virol. 2002 Aug;76(16):8179-88 PMID: 12134023
  5. Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection.
    J Virol. 2009 Sep;83(18):9068-78 PMID: 19605492
  6. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects.
    J Exp Med. 2005 Sep 5;202(5):673-85 PMID: 16147978
  7. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.
    Annu Rev Immunol. 2007;25:587-617 PMID: 17378764
  8. Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope.
    J Immunol. 2002 Aug 15;169(4):2172-9 PMID: 12165547
  9. The immune response to Epstein-Barr virus.
    Microbes Infect. 2004 Aug;6(10):937-45 PMID: 15310471
  10. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
    J Immunol. 2010 May 15;184(10):5895-902 PMID: 20385879
  11. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells.
    Eur J Immunol. 2004 Sep;34(9):2500-9 PMID: 15307182
  12. Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative epstein-barr virus.
    J Virol. 2005 Jun;79(12):7641-7 PMID: 15919916
  13. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
    J Exp Med. 2006 Apr 17;203(4):995-1006 PMID: 16549597
  14. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.
    Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2165-70 PMID: 20133861
  15. Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones.
    J Virol. 1991 Jul;65(7):3821-8 PMID: 1710291
  16. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification.
    J Virol. 2009 Aug;83(15):7749-60 PMID: 19439479
  17. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.
    EMBO J. 2000 Jun 15;19(12):3080-9 PMID: 10856251
  18. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.
    J Virol. 2005 May;79(9):5477-88 PMID: 15827162
  19. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.
    J Virol. 2005 Apr;79(8):4896-907 PMID: 15795275
  20. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
    Virology. 1995 Dec 20;214(2):633-7 PMID: 8553567
  21. Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth.
    J Gen Virol. 2005 Nov;86(Pt 11):3009-3019 PMID: 16227222
  22. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells.
    J Immunol. 2006 Sep 15;177(6):3746-56 PMID: 16951335
  23. Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis.
    Clin Exp Immunol. 2008 Aug;153(2):231-9 PMID: 18549439
  24. Cyclical expression of EBV latent membrane protein 1 in EBV-transformed B cells underpins heterogeneity of epitope presentation and CD8+ T cell recognition.
    J Immunol. 2009 Feb 15;182(4):1919-28 PMID: 19201845
  25. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
    PLoS One. 2007 Jul 04;2(7):e583 PMID: 17611619
  26. CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.
    J Exp Med. 2005 Feb 7;201(3):349-60 PMID: 15684323
  27. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines.
    J Immunol. 2008 Feb 1;180(3):1643-54 PMID: 18209060
  28. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    PLoS Pathog. 2009 Jun;5(6):e1000490 PMID: 19557156
  29. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease.
    Mod Pathol. 1996 Jun;9(6):621-30 PMID: 8782198
  30. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Eur J Cell Biol. 2012 Jan;91(1):31-5 PMID: 21458882
  31. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.
    J Immunol. 1999 Feb 1;162(3):1827-35 PMID: 9973448
  32. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.
    Blood. 2004 Feb 15;103(4):1408-16 PMID: 14563644
  33. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected b cells following capture of BHRF1 antigen.
    J Immunol. 2005 Dec 15;175(12):7939-46 PMID: 16339529
  34. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses.
    J Immunol Methods. 2003 Apr 1;275(1-2):19-29 PMID: 12667667
  35. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells.
    J Immunol. 2002 Aug 1;169(3):1593-603 PMID: 12133989
  36. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.
    PLoS Pathog. 2009 Jan;5(1):e1000255 PMID: 19119421
  37. The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function.
    J Virol. 2008 Mar;82(5):2385-93 PMID: 18094150
  38. Endogenous MHC class II processing of a viral nuclear antigen after autophagy.
    Science. 2005 Jan 28;307(5709):593-6 PMID: 15591165
  39. Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.
    J Virol. 2008 Apr;82(8):3903-11 PMID: 18272580
  40. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.
    Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716-20 PMID: 202961
  41. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases.
    J Infect Dis. 1989 Oct;160(4):589-98 PMID: 2551973
  42. T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.
    PLoS Pathog. 2009 Dec;5(12):e1000699 PMID: 20019813
  43. Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity.
    Microbes Infect. 2010 Mar;12(3):173-81 PMID: 20004735
  44. Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines.
    Blood. 2008 Feb 1;111(3):1334-43 PMID: 17942757
  45. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
    Blood. 2007 Aug 15;110(4):1123-31 PMID: 17468341
  46. Detection of T-cell degranulation: CD107a and b.
    Methods Cell Biol. 2004;75:497-512 PMID: 15603439
  47. Post-transplant lymphoproliferative disorders.
    Annu Rev Med. 2005;56:29-44 PMID: 15660500
  48. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
    J Immunol. 2009 Feb 15;182(4):1799-809 PMID: 19201831
  49. The wide diversity and complexity of peptides bound to class II MHC molecules.
    Curr Opin Immunol. 2006 Feb;18(1):70-7 PMID: 16316750
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
1550-6606
Published
2011-07-01
Epub
2011-00-27
Pages
92-101
Language
English
Region
United States
NLM ID
2985117R
PMCID
PMC3154640
Subset
IM
Grants
Medical Research Council · G0901755-E02/1 · United Kingdom
Medical Research Council · G0901755 · United Kingdom
PHS HHS · G0901755-E02/1 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com